Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:BLU NYSEAMERICAN:CVM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS HealthC$0.00C$8.58▼C$19.90C$2.47B-0.2859,471 shs28,666 shsCVMCel-Sci$1.39+7.2%$3.33$0.89▼$13.48$11.83M0.7199,678 shs655,119 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%CVMCel-Sci+8.33%-18.75%-70.18%-73.47%-82.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS HealthC$0.00C$8.58▼C$19.90C$2.47B-0.2859,471 shs28,666 shsCVMCel-Sci$1.39+7.2%$3.33$0.89▼$13.48$11.83M0.7199,678 shs655,119 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%CVMCel-Sci+8.33%-18.75%-70.18%-73.47%-82.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUBELLUS Health 0.00N/AN/AN/ACVMCel-Sci 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUBELLUS HealthC$16K0.00N/A4.67C$2.91 per share0.00CVMCel-SciN/AN/AN/AN/A$2.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUBELLUS Health-C$86.79M-C$0.96N/AN/AN/AN/A-26.76%-16.70%N/ACVMCel-Sci-$25.41M-$9.77N/AN/AN/AN/A-226.09%-102.18%N/ALatest BLU, CVM, and OXB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/17/2026Q1 2026CVMCel-SciN/A-$0.68N/A-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLUBELLUS HealthN/AN/AN/AN/AN/ACVMCel-SciN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUBELLUS Health0.3233.4216.40CVMCel-Sci0.451.391.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUBELLUS Health90.41%CVMCel-Sci12.08%Insider OwnershipCompanyInsider OwnershipBLUBELLUS Health10.26%CVMCel-Sci9.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUBELLUS Health74126.81 millionN/ANot OptionableCVMCel-Sci438.49 million7.65 millionOptionableBLU, CVM, and OXB HeadlinesRecent News About These CompaniesCEL-SCI Announces Closing of Public OfferingMay 13 at 3:00 PM | businesswire.comCEL-SCI Corporation Announces Pricing of Public OfferingMay 11, 2026 | businesswire.comCEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi ArabiaMay 11, 2026 | pharmiweb.comPCEL-SCI CorporationMay 5, 2026 | edition.cnn.comCEL-SCI Reports Fiscal First Quarter 2026 ResultsFebruary 18, 2026 | finance.yahoo.comCEL-SCI (CVM) price target decreased by 91.67% to 25.50February 4, 2026 | msn.comWhy did CVM shares rally over 7% today?January 27, 2026 | msn.comCEL-SCI Reports Fiscal 2025 ResultsDecember 29, 2025 | finance.yahoo.comCEL-SCI files to sell 375,000 shares of common stock for holdersNovember 7, 2025 | msn.comCel-Sci Extends Shareholder Rights Agreement to 2030November 5, 2025 | msn.comCEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025October 20, 2025 | newsfilecorp.comNCEL-SCI Corporation to Present at LD Micro "Main Event" Investor ConferenceOctober 10, 2025 | newsfilecorp.comNCEL-SCI Announces Closing of $10 Million Public OfferingAugust 29, 2025 | businesswire.comCEL-SCI stock falls after pricing $10M public offering at discountAugust 28, 2025 | ca.investing.comCEL-SCI Announces Pricing of $10 Million Public OfferingAugust 27, 2025 | businesswire.comCEL-SCI Announces Proposed Public OfferingAugust 27, 2025 | businesswire.comCEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last yearAugust 14, 2025 | msn.comCel-Sci: Fiscal Q3 Earnings SnapshotAugust 14, 2025 | timesunion.comTCEL-SCI files for breakthrough designation for Multikine in Saudi ArabiaAugust 13, 2025 | msn.comCEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA TimelineAugust 13, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesA Diamond Quality Entry in DIA ETF, or Is It Time to Get Out?By Thomas Hughes | April 17, 2026AST SpaceMobile Drops 15% After Blue Origin Satellite MishapBy Jessica Mitacek | April 22, 2026AST SpaceMobile Gets FCC Green Light for Direct-to-Device Service After Launch SetbackBy Jessica Mitacek | April 28, 2026Shift4’s Explosive Growth Comes With High-Stakes RiskBy Peter Frank | April 29, 2026Netflix's Pivot to Profit: The New Discretionary Blue ChipBy Jeffrey Neal Johnson | April 25, 2026BLU, CVM, and OXB Company DescriptionsBELLUS Health TSE:BLUBluenergies Ltd. is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Lemon Lake Property.Cel-Sci NYSEAMERICAN:CVM$1.39 +0.09 (+7.23%) As of 12:39 PM Eastern This is a fair market value price provided by Massive. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Dividend Growth or High Yield: The Income Investor's Bet Karman: Defense Darling's Outlook Strengthens After 40% Drop Nebius Upside Expands as AI Feedback Loop Intensifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
